AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Pillar Biosciences and AstraZeneca Partner to Accelerate Access to Liquid Biopsy Testing

NextEdge Admin

10 Sep 2024

1 min 49 sec

Pillar Biosciences, Inc. has partnered with AstraZeneca to enhance access to molecular testing using rapid Next Generation Sequencing (NGS)-based liquid biopsy panels for detecting cancer-related genetic variants, with an initial focus on the UK and European markets. This collaboration aims to streamline the identification of tumors with actionable genomic alterations through local laboratories, accelerating diagnostic testing.

The partnership will leverage Pillar’s oncoReveal™ liquid biopsy NGS panels, including the Core LBx, Essential LBx, and Fusion LBx panels, which analyze circulating tumor DNA (cfDNA) and RNA (cfRNA). These panels can be used by any laboratory, offering results in under three days. Notably, the panels enable the testing of samples from over 22 patients in a single Illumina NextSeq™ run, enhancing scalability and cost-effectiveness.

Dan Harma, Chief Commercial Officer at Pillar, highlighted the importance of affordable, easy-to-use NGS kits for providing oncologists with actionable results in a timely manner. John Longshore, AstraZeneca's Head of Scientific Affairs, emphasized the need for decentralized NGS solutions to improve global access to targeted therapies, noting that Pillar’s panels support high-quality, rapid workflows that are integral to their mission.